BioFocus DPI and ZoBio Announce Marketing Agreement

BioFocus DPI and ZoBio announced that they have signed a worldwide marketing and sales agreement for ZoBio’s fragment-based NMR technologies. Under the terms of the agreement BioFocus DPI will sell ZoBio’s services either as a stand-alone offering or in combination with BioFocus DPI’s drug discovery offering.

ZoBio has extensive experience in fragment–based screening using its patented Target Immobilized NMR Screening (TINS) technology. TINS can allow screening of drug fragment libraries with high sensitivity using only a few mg of target protein. An additional advantage of TINS screening is that it can be achieved in a few weeks, accelerating the drug discovery process.

“The addition of the ZoBio technology to BioFocus DPI’s offerings will enhance our hit finding capabilities” said Chris Newton, Senior Vice President of BioFocus DPI. “The technology will expand our fragment-based screening obtained through the acquisition of Sareum’s X-ray crystallography”.

”We are pleased that BioFocus has selected ZoBio as a strategic partner for their fragment-based drug discovery services” said Gregg Siegal, CSO of ZoBio. “We feel the combination will offer customers proven, cutting edge technologies to meet their biggest drug discovery challenges.”